ClinicalTrials.gg
TerminatedNCT05555251CONTRASTUpdated Dec 16, 2024

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

A Phase 1/2 interventional study of BI-1607 and BI-1607 in HER2-positive Breast Cancer, HER2-positive Gastric Cancer and HER2-positive Metastatic Breast Cancer, sponsored by BioInvent International AB. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

Why this study was terminated
After the completion of phase IA, for business reasons it was decided to terminate the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Enrollment
546th of 580
18 · median 273
Started
2022
with 30 others
Phase 1/2
28 of 678
9 open now
Registered
556th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 546th largest by enrollment of the 580 interventional ones that give a count, is one of 31 that started in 2022, is one of 28 in phase 1/2, and was the 556th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy. However, many patients remain uncured and develop resistance to trastuzumab resulting in relapse or progression of the disease. BI-1607, a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targets CD32b (Fc Gamma Receptor IIB), it is intended to enhance the efficacy and overcome resistance to existing cancer treatments such as trastuzumab.

This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy.

Read the detailed description

This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy.

The Phase 1 part of the trial is a dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors, the aim is to assess safety and tolerability and to determine the recommended phase II dose of BI-1607 in combination with trastuzumab.

The selected dose of BI-1607 will be studied in a subsequent Phase 2a part of the trial along with trastuzumab in 2 open-label, expansion cohorts of 15 evaluable subjects each. The first cohort will enroll subjects with locally advanced or metastatic HER2+ breast cancer, and the second will recruit subjects with HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. The aim of the phase 2a is to collect additional safety data to further support the recommended dose, and to detect early signs of clinical activity.

03

Conditions studied

  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER2-positive Metastatic Breast Cancer
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Gastric Adenocarcinoma

Keywords

  • HER2-positive
  • solid tumours
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Is willing and able to provide written for the trial.
  • Is ≥18 years of age on day of signing informed consent.
  • Has received standard of care or is intolerant to standard of care antineoplastic therapy. Subjects who are intolerant to trastuzumab cannot be enrolled in the study.
  • Has at least 1 lesion as defined by v1.1 criteria.
  • Has a locally confirmed + tumor.
  • Must have progressive disease after the last . In addition, subjects must have received the following previous lines of treatment:

    1. Prior lines of treatment including trastuzumab and chemotherapy.
    2. At least one prior line of treatment with an antibody-drug conjugate (ADC) (eg, trastuzumab-emtansine [TDM-1, or trastuzumab-deruxtecan]).

Main Exclusion Criteria:

  • Needs doses of prednisolone >10 mg daily (or equipotent doses of other ) while on the trial other than as premedication.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Has cardiac or renal amyloid light-chain amyloidosis.
  • Has had lung disease requiring systemic corticosteroid treatment within the last 6 months of enrollment.
  • Has an active, known, or suspected disease.
  • Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals.
  • Has presence of chronic .
  • Has had an allogenic tissue/solid organ transplant.
  • Has uncontrolled or significant cardiovascular disease.
  • Has a known additional of another type, except for adequately treated cone-biopsied carcinoma in situ (eg, breast carcinoma, cervical cancer in situ), adequately controlled superficial bladder cancer, and basal or squamous cell carcinoma of the skin.
  • Has a diagnosis of primary or acquired immunodeficiency disorder or is taking any other form of therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Phase I -Dose escalation

    Dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors.

    Drug: BI-1607 · Drug: Trastuzumab

  • Experimental
    Phase 2a - Expansion cohorts

    Dose expansion study of BI-1607 combined with trastuzumab in cohort 1: HER2 positive locally advanced or metastatic HER2+ breast cancer and cohort 2: metastatic gastric or gastroesophageal junction adenocarcinoma

    Drug: BI-1607 · Drug: Trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumab

    Adverse events (AEs) and serious adverse events (SAEs) (graded according to the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) and their causality in relation to BI-1607 or to the combination with trastuzumab

    Time frame: End of treatment visit or 30 days after last dose of study drug.

  2. Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.

    Occurrence of DLTs

    Time frame: 22 days

Secondary outcomes

  1. Assessment of the pharmacokinetic (PK) profile of BI-1607 when administered every 3 weeks in combination with trastuzumab

    The PK parameters will include area under the serum concentration-time curve, maximum concentration, time to maximum concentration, and terminal half-life

    Time frame: 90 days after the last dose of BI-1607

  2. Assessment of the immunogenicity of BI-1607 when administered in combination with trastuzumab

    Antidrug antibody response to BI-1607 in blood serum

    Time frame: 90 days after the last dose of BI-1607

  3. Assessment of the CD32b receptor occupancy (RO) of BI-1607 on B cells when administered in combination with trastuzumab

    RO on circulating B lymphocytes

    Time frame: 30 days after the last dose of BI-1607

  4. Assessment of the possible antitumor activity of BI-1607 in combination with trastuzumab

    Best tumor response, objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, progression-free survival (PFS), time to response, duration of response (DOR) and OS

    Time frame: 1 year after the last treatment

Other outcomes

  1. Exploratory: investigate expression levels of Fc receptors, and other immunological markers on immune cells infiltrating the tumor

    Expression levels of Fc receptors (eg, CD32b) and other markers of immunological activity using immunohistochemistry (IHC) and/or nucleotide-based assays using tissue samples

    Time frame: 1 day

  2. Exploratory: investigate the genetic background of subjects with respect to FcgammaR isoforms and explore a potential correlation of the genetic background with clinical responses

    Determination of Fcgamma receptor isoforms using nucleotide-based assays on genetic material extracted from whole blood

    Time frame: 1 day

  3. Exploratory: explore any exposure-response and/or exposure-safety relationship between BI-1607 serum concentrations and clinical outcome

    Correlation of BI-1607 PK and antitumor activity measures, as well as to safety measures of interest

    Time frame: 1 day

07

Study locations

6 sites
  • Evang. Kliniken Essen-Mitte
    Essen, 45136, Germany
  • Krankenhaus Nordwest
    Frankfurt, 60488, Germany
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Complejo hospitalario Ruber Juan Bravo
    Madrid, 28034, Spain
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Publications

  • Cortes J, Priego A, Garralda E, Rojas K, Lord SR, Goetze TO, Kuemmel S, Crabb SJ, Parra-Guillen ZP, Borggren M, Karlsson I, Lindahl D, Martensson L, Oldham R, Ropenga A, Teige I, Wallin J, Frendeus B, McAllister A. A First-in-Class mAb (BI-1607) Targeting FcgammaRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. Clin Cancer Res. 2025 Dec 1;31(23):4953-4963. doi: 10.1158/1078-0432.CCR-25-1348. PubMed 41071338 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Feb 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 26, 2022
StartActual
Jul 28, 2022
Primary completionActual
Feb 7, 2024
CompletionActual
Feb 7, 2024
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05555251
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Sep 26, 2022
Start date
Jul 28, 2022
Primary completion
Feb 7, 2024
Completion
Feb 7, 2024
Last update
Dec 16, 2024

Study contacts

Andres McAllister, MD, PhD
study director · BioInvent International AB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CNTN4 Monoclonal Antibody GENA-104A16

Start the discussion